Real-World study tracks how IBD patients choose between IV and injectable vedolizumab
NCT ID NCT04989907
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study observed 92 adults with Crohn's disease or ulcerative colitis who were receiving vedolizumab either as an intravenous infusion or a subcutaneous injection. Researchers tracked treatment patterns, such as whether patients stayed on their current form or switched, over 12 months. The goal was to understand real-world choices and outcomes without influencing how patients were treated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vedolizumab
What this could lead to
If successful, this study could help doctors and patients make more informed decisions about which form of vedolizumab (IV or injection) works best in daily life.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient or doctor preferences rather than the treatment itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bauchzentrum INSELSPITAL, Universitatsspital Bern
Bern, 3010, Switzerland
-
Clarunis AG
Basel, 4002, Switzerland
-
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum
Bern, 3012, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Universitatsspital Zurich
Zurich, 8091, Switzerland
-
Zentrum fur Gastroenterologie und Hepatologie AG
Zurich, 8048, Switzerland